Effect of Insulin Glulisin on postprandial plasma glucose levels in obese subjectts with type 2 diabetes after a standard meal in comparison to Insulin Lispro

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-005914-18-DE

Enrollment

Registered

2006-01-02

Start date

2006-03-15

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obese subjects with type 2 diabetes mellitus

Interventions

Trade Name: Apidra Product Name: Apidra Pharmaceutical Form: Injection* INN or Proposed INN: Insulin Glulisin Concentration unit: IU international unit(s) Concentration type: range Concentration numbe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic subjects Age: > 30, 12 months BMI: > 28, =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Pregnancy Nursing Medication known to influence insulin sensitivity Alcohol abuse Drug abuse Psychiatric illness

Design outcomes

Primary

Measure	Time frame
Main Objective: Area under the curve (AUC) plasma glucose 0-1 h;Secondary Objective: AUC plasma glucose 0-4 h (end) Difference plasma glucose at 1 h postprandially AUC plasma insulin 0-1 h AUC plasma insulin 0-4 h (end);Primary end point(s): Area under the curve (AUC) plasma glucose 0-1 h	—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026